PT1914237E - Compostos antivíricos de éster fosfonato - Google Patents

Compostos antivíricos de éster fosfonato Download PDF

Info

Publication number
PT1914237E
PT1914237E PT80014087T PT08001408T PT1914237E PT 1914237 E PT1914237 E PT 1914237E PT 80014087 T PT80014087 T PT 80014087T PT 08001408 T PT08001408 T PT 08001408T PT 1914237 E PT1914237 E PT 1914237E
Authority
PT
Portugal
Prior art keywords
phosphonate ester
antiviral compounds
disorders
compounds
osteoporosis
Prior art date
Application number
PT80014087T
Other languages
English (en)
Portuguese (pt)
Inventor
Ganesh D Kini
James R Beadle
Karl Y Hostetler
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT1914237E publication Critical patent/PT1914237E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/404—Esters of poly(thio)phosphonic acids containing hydroxy substituents in the hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4025—Esters of poly(thio)phosphonic acids
    • C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/48—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT80014087T 1999-12-03 2000-12-04 Compostos antivíricos de éster fosfonato PT1914237E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16881399P 1999-12-03 1999-12-03
US20571900P 2000-05-19 2000-05-19

Publications (1)

Publication Number Publication Date
PT1914237E true PT1914237E (pt) 2014-09-09

Family

ID=26864475

Family Applications (2)

Application Number Title Priority Date Filing Date
PT00982468T PT1233770E (pt) 1999-12-03 2000-12-04 Compostos de fosfonato
PT80014087T PT1914237E (pt) 1999-12-03 2000-12-04 Compostos antivíricos de éster fosfonato

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT00982468T PT1233770E (pt) 1999-12-03 2000-12-04 Compostos de fosfonato

Country Status (18)

Country Link
US (14) US6716825B2 (OSRAM)
EP (1) EP1233770B1 (OSRAM)
JP (4) JP4993649B2 (OSRAM)
KR (1) KR20020073342A (OSRAM)
CN (1) CN1414854B (OSRAM)
AT (1) ATE385797T1 (OSRAM)
AU (3) AU785355B2 (OSRAM)
BR (1) BR0016058A (OSRAM)
CA (2) CA2393410C (OSRAM)
CY (1) CY1107927T1 (OSRAM)
DE (1) DE60038038T2 (OSRAM)
DK (2) DK1914237T3 (OSRAM)
ES (2) ES2498046T3 (OSRAM)
HK (1) HK1050627B (OSRAM)
MX (1) MXPA02005490A (OSRAM)
PT (2) PT1233770E (OSRAM)
RU (1) RU2258707C2 (OSRAM)
WO (1) WO2001039724A2 (OSRAM)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
BR0016058A (pt) * 1999-12-03 2003-07-15 Univ California San Diego Compostos de fosfonato
US7163932B2 (en) * 2001-06-20 2007-01-16 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
FR2837490B1 (fr) * 2002-03-21 2009-04-17 Univ Paris 13 Nouveaux derives de bisphosphonates, leurs preparations et utilisations
ATE455121T1 (de) * 2001-07-16 2010-01-15 Univ Paris 13 Herstellungsverfahren von derivate von bisphosphonaten
AU2003219999A1 (en) * 2002-03-06 2003-09-22 Lifizz, Inc. Effervescent compositions comprising bisphosphonates and methods related thereto
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
JP4942915B2 (ja) * 2002-04-26 2012-05-30 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖプロテアーゼ阻害剤化合物のホスホネートアナログの細胞蓄積
RU2309747C2 (ru) * 2002-09-18 2007-11-10 Михаил Владимирович Кутушов Применение 2-хлорэтилфосфоновой кислоты и ее солей в качестве противоопухолевого средства
AU2003901813A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Pharmaceutical derivatives
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
MXPA05011296A (es) 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
EP1678321A1 (en) 2003-10-24 2006-07-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005056019A1 (ja) * 2003-12-12 2005-06-23 Astellas Pharma Inc. 悪性黒色腫治療剤
JP2007515495A (ja) 2003-12-22 2007-06-14 ギリアード サイエンシーズ， インコーポレイテッド ４’−置換カルボビル誘導体およびアバカビル誘導体ならびにｈｉｖおよびｈｃｖ抗ウイルス活性を有する関連化合物
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
WO2006076015A2 (en) * 2004-04-30 2006-07-20 The Regents Of The University Of California 1-[2-(phosphonomethoxy)ethyl]-cytosine and analogs thereof
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
WO2006055525A2 (en) * 2004-11-15 2006-05-26 Ceptyr, Inc. Protein tyrosine phosphatase inhibitors and methods of use thereof
EP1831235B1 (en) 2004-12-16 2013-02-20 The Regents of The University of California Lung-targeted drugs
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20060219637A1 (en) * 2005-03-29 2006-10-05 Killeen Kevin P Devices, systems and methods for liquid chromatography
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
JP2008538354A (ja) * 2005-04-08 2008-10-23 キメリクス，インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
EP1879657A2 (en) * 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
US7914810B2 (en) 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
US8114843B2 (en) 2005-11-18 2012-02-14 The Regents Of The University Of California Photoreactive regulator of protein function and methods of use thereof
WO2007130783A2 (en) 2006-05-03 2007-11-15 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
EP2155257B1 (en) * 2007-04-27 2016-10-05 Chimerix, Inc. Methods of reducing nephrotoxicity in subjects administered with nucleoside
EP2234623A4 (en) * 2007-12-27 2012-03-28 Epiphany Biosciences ANTIVIRAL CONNECTIONS
CN102670628B (zh) * 2008-01-25 2015-11-25 奇默里克斯公司 治疗病毒感染的方法
HRP20120700T1 (hr) 2008-07-08 2012-09-30 Gilead Sciences SOLI SPOJEVA INHIBITORA HIV-a
US8628812B2 (en) 2008-12-30 2014-01-14 Pepsico, Inc. Preservative system for acidic beverages based on sequestrants
EP2270021A1 (en) * 2009-06-18 2011-01-05 Centre National de la Recherche Scientifique Phosphonates synthons for the synthesis of phosphonates derivatives showing better bioavailability
WO2011005510A2 (en) * 2009-06-22 2011-01-13 Cerapedics, Inc. Peptide conjugates and uses thereof
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
EP2462152A4 (en) 2009-08-03 2013-02-13 Chimerix Inc COMPOSITION AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS AND TEMPORED VIRUSES
JP5748759B2 (ja) * 2009-10-02 2015-07-15 ストレイトマーク・ホールディング・アーゲー アミノヒドロキシジホスホン酸の製造方法
HUE032860T2 (en) 2010-02-12 2017-11-28 Chimerix Inc A method for treating a virus infection
EP2558466A4 (en) 2010-04-14 2013-11-13 Univ California PHOSPHONATES WITH REDUCED TOXICITY FOR THE TREATMENT OF VIRUS INFECTIONS
US9278135B2 (en) 2010-04-26 2016-03-08 Chimerix Inc. Methods of treating retroviral infections and related dosage regimes
ES2604137T3 (es) * 2010-08-31 2017-03-03 Chimerix, Inc. Derivados de éster de fosfonato y métodos de síntesis de los mismos
AU2015201895B2 (en) * 2010-08-31 2016-11-17 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
WO2013033450A2 (en) * 2011-08-31 2013-03-07 Mallinckrodt Llc Remote assembly of targeted nanoparticles using h-phosphonate-ene/-yne hydrophosphonylation reactions
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US20150209273A1 (en) * 2012-08-28 2015-07-30 Glaxosmithkline Llc Pharmaceutical Compositions
EP3401320B1 (en) 2013-03-15 2020-05-13 The Regents of the University of California Acyclic nucleoside phosphonate diesters for use in treating human papilloma virus, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, or vulvar intraepithelial neoplasia
BR112016010862B1 (pt) 2013-11-15 2022-11-29 Chimerix, Inc Formas mórficas de ésteres de hexadeciloxipropilfosfonato, seu método de preparo e composição compreendendo a dita forma mórfica
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
RS63250B1 (sr) 2014-09-15 2022-06-30 Univ California Nukleotidni analozi
WO2016069630A1 (en) 2014-10-27 2016-05-06 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters bearing at least one deuterium atom
HK1247829A1 (zh) 2015-03-06 2018-10-05 Atea Pharmaceuticals, Inc. 用於治疗HCV的β-D-2'-脱氧-2'Α-氟-2'-β-C-取代-2-改性N6-取代的嘌呤核苷酸
WO2016174674A1 (en) * 2015-04-27 2016-11-03 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
WO2017048252A1 (en) 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
EP3474822B1 (en) 2016-06-28 2025-07-09 Emergent BioDefense Operations Lansing LLC Formulations of brincidofovir
RU2628456C1 (ru) * 2016-06-29 2017-08-17 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Новые пиримидиновые ингибиторы репликации аденовируса человека
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3512863B1 (en) 2016-09-07 2021-12-08 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
RU2670204C1 (ru) * 2017-12-01 2018-10-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Производные 2-тиоурацила, обладающие противоаденовирусной активностью
US11447512B2 (en) * 2017-12-21 2022-09-20 Shenzhen Targetrx, Inc. Antiviral nucleoside reverse transcriptase inhibitor
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
KR20220083673A (ko) 2019-08-22 2022-06-20 에모리 유니버시티 뉴클레오사이드 전구약물 및 이와 관련된 용도
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CR20230100A (es) 2020-08-24 2023-04-28 Gilead Sciences Inc Compuestos fosfolípidos y usos de los mismos
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CN117285566A (zh) * 2022-06-24 2023-12-26 润佳（苏州）医药科技有限公司 一种膦酸酯类化合物及其医药用途
CA3262284A1 (en) 2022-07-21 2024-01-25 Antiva Biosciences, Inc. Pharmaceutical compositions and forms for the treatment of human papillomavirus (HPV) infection and HPV-induced neoplasm

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1944530A (en) * 1929-04-08 1934-01-23 Ig Farbenindustrie Ag Phosphoric acid esters
DE2009341C3 (de) * 1970-02-27 1979-06-21 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen 3-Octadecyloxy-propanol-(l)-phosphorsäure-monocholinester und Verfahren zu dessen Herstellung
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
FR2586685B1 (fr) * 1985-09-03 1987-12-11 Protex Manuf Prod Chimiq Procede de preparation de nouveaux agents dispersants cationiques
SU1594953A1 (ru) * 1988-12-30 1991-05-15 Институт Молекулярной Биологии Им.В.А.Энгельгардта Аммонийна соль 9-(4-гидрофосфорил-2-оксабутил)гуанина, обладающа избирательной активностью против вируса простого герпеса
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
ES2118069T3 (es) * 1990-09-14 1998-09-16 Acad Of Science Czech Republic Profarmacos de fosfonatos.
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
JPH05339280A (ja) * 1991-04-26 1993-12-21 Japan Tobacco Inc （ｎ−二環置換）アミノメチレンビスフォスフォン酸誘導体
JP3341303B2 (ja) * 1991-07-11 2002-11-05 東レ株式会社 メチレンジホスホン酸誘導体、その製造方法およびその医薬用途
US5879700A (en) * 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
DE69330114T2 (de) 1992-07-10 2001-08-02 Toray Industries, Inc. Methandiphosphonat-derivat, dessen produktion und dessen verwendung als arzneimittel
JP3580377B2 (ja) * 1993-06-29 2004-10-20 三菱化学株式会社 ホスホナートヌクレオチドエステル誘導体
EP0632048B1 (en) 1993-06-29 2001-03-21 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
US5627185A (en) * 1994-11-23 1997-05-06 Gosselin; Gilles Acyclovir derivatives as antiviral agents
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
DE69737385T2 (de) * 1996-12-19 2007-10-25 Kao Corp. Zusammensetzung für die beschichtung von zähnen
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
NZ550116A (en) 1997-08-18 2008-03-28 Neurochem Int Ltd Phosphono-carboxylate compounds for treating amyloidosis
FR2781228B1 (fr) 1998-07-16 2000-09-29 Pf Medicament Phosphonates insatures derives d'indole
BR0016058A (pt) * 1999-12-03 2003-07-15 Univ California San Diego Compostos de fosfonato

Also Published As

Publication number Publication date
US8309565B2 (en) 2012-11-13
US20070161602A1 (en) 2007-07-12
US7094772B2 (en) 2006-08-22
EP1233770B1 (en) 2008-02-13
WO2001039724A2 (en) 2001-06-07
WO2001039724A3 (en) 2001-10-18
DK1233770T3 (da) 2008-06-16
CA2393410A1 (en) 2001-06-07
AU2006252074A1 (en) 2007-01-18
US20150051174A1 (en) 2015-02-19
US9649321B2 (en) 2017-05-16
US10071110B2 (en) 2018-09-11
US9206208B2 (en) 2015-12-08
DE60038038D1 (en) 2008-03-27
BR0016058A (pt) 2003-07-15
US7452898B2 (en) 2008-11-18
AU1949701A (en) 2001-06-12
AU2010257309B2 (en) 2014-04-10
US20040127735A1 (en) 2004-07-01
CA2393410C (en) 2011-10-11
US20060281706A1 (en) 2006-12-14
JP2004500352A (ja) 2004-01-08
HK1050627B (en) 2008-12-24
JP4993649B2 (ja) 2012-08-08
US20140045794A1 (en) 2014-02-13
US20160067268A1 (en) 2016-03-10
JP5963787B2 (ja) 2016-08-03
AU2006252074B2 (en) 2010-09-30
US7687480B2 (en) 2010-03-30
CN1414854A (zh) 2003-04-30
CY1107927T1 (el) 2013-09-04
EP1233770A4 (en) 2003-04-16
US20120058975A1 (en) 2012-03-08
JP2014074065A (ja) 2014-04-24
US20050176673A1 (en) 2005-08-11
US20040019232A1 (en) 2004-01-29
JP2015078230A (ja) 2015-04-23
PT1233770E (pt) 2008-04-24
RU2258707C2 (ru) 2005-08-20
EP1233770A2 (en) 2002-08-28
US7034014B2 (en) 2006-04-25
US6716825B2 (en) 2004-04-06
JP2011246475A (ja) 2011-12-08
JP5963894B2 (ja) 2016-08-03
US7098197B2 (en) 2006-08-29
US7790703B2 (en) 2010-09-07
US20080103115A1 (en) 2008-05-01
MXPA02005490A (es) 2004-09-10
CA2747954A1 (en) 2001-06-07
AU2010257309A1 (en) 2011-01-13
US8008308B2 (en) 2011-08-30
ES2498046T3 (es) 2014-09-24
HK1050627A1 (en) 2003-07-04
DE60038038T2 (de) 2009-02-12
AU785355B2 (en) 2007-02-01
US20130045950A1 (en) 2013-02-21
US20050182019A1 (en) 2005-08-18
US20100173870A1 (en) 2010-07-08
US8710030B2 (en) 2014-04-29
CN1414854B (zh) 2015-08-19
ATE385797T1 (de) 2008-03-15
US8889658B2 (en) 2014-11-18
KR20020073342A (ko) 2002-09-23
DK1914237T3 (da) 2014-09-15
CA2747954C (en) 2014-02-25
US20170239279A1 (en) 2017-08-24
ES2300281T3 (es) 2008-06-16

Similar Documents

Publication Publication Date Title
PT1914237E (pt) Compostos antivíricos de éster fosfonato
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
LU91145I9 (OSRAM)
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
BG104727A (en) Pharmaceutical composition of topiramate
MXPA02008233A (es) Compuestos de pteridina para tratamiento de psoriasis.
GB9813540D0 (en) Chemical compounds
MY146809A (en) Treatment and prevention of osteoporosis
EP0911321A3 (en) Compounds for the treatment of osteoporosis
GB0129260D0 (en) Pharmaceutical compositions and their uses
YU50800A (sh) Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola
AP9801269A0 (en) Prostaglandin agonists.
AU7566601A (en) Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases
MXPA04004498A (es) Derivados de n-adamantilmetil e intermediarios como composiciones farmaceuticas y procesos para su preparacion.
PL367682A1 (en) Dolastatin 10 derivatives
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
JO2663B1 (en) Abandronate is a large dose
AU7096201A (en) Phospholipid derivatives of valproic acid and mixtures thereof
IL150060A0 (en) Novel purines
HUP0202969A2 (hu) Sztatinok alkalmazása csontlebontó sejtek képződésének gátlására és ezeket tartalmazó gyógyszerkészítmények
IL145122A0 (en) C16 unsaturated fp-selective prostaglandin analogs
AU1022999A (en) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
CA2431515A1 (en) Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition, and use thereof
MXPA02001204A (es) Compuestos calciliticos.
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents